Kayne Anderson Rudnick Investment Management
MRNA icon

Kayne Anderson Rudnick Investment Management’s Moderna MRNA Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-19
Closed -$524 – 1085
2025
Q2 		$524 Buy
+19
New +$500 ﹤0.01% 988
2024
Q4 		– Sell
-21,719
Closed -$1.45M – 1016
2024
Q3 		$1.45M Sell
21,719
-654
-3% -$60K ﹤0.01% 365
2024
Q2 		$2.66M Sell
22,373
-503
-2% -$63.7K 0.01% 315
2024
Q1 		$2.44M Sell
22,876
-822
-3% -$82.9K 0.01% 321
2023
Q4 		$2.36M Sell
23,698
-1,022
-4% -$86K 0.01% 327
2023
Q3 		$2.55M Sell
24,720
-186
-0.7% -$20.7K 0.01% 329
2023
Q2 		$3.03M Sell
24,906
-374
-1% -$49.9K 0.01% 323
2023
Q1 		$3.88M Hold
25,280
– – 0.01% 308
2022
Q4 		$4.54M Sell
25,280
-1,070
-4% -$175K 0.01% 301
2022
Q3 		$3.12M Buy
+26,350
New +$4M 0.01% 311
2022
Q2 		– Sell
-6
Closed -$1K – 653
2022
Q1 		$1K Buy
6
+1
+20% +$168 ﹤0.01% 638
2021
Q4 		$1K Buy
+5
New +$1.46K ﹤0.01% 619

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's MRNA Position: Q3 2025 in Review

Kayne Anderson Rudnick Investment Management sold out of Moderna (MRNA) in Q3 2025, closing a stake of 19 shares — an estimated $524 sold.

Kayne Anderson Rudnick Investment Management first reported a position in MRNA in Q4 2021 and held it in 12 quarters. The position peaked at $4.54M in Q4 2022. 644 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

  • Kayne Anderson Rudnick Investment Management reported no remaining Moderna position as of Q3 2025 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 19 Moderna shares in Q3 2025, an estimated $524.
  • Kayne Anderson Rudnick Investment Management first reported a position in Moderna in Q4 2021 and held it in 12 quarters.
  • Kayne Anderson Rudnick Investment Management's Moderna position peaked at $4.54M in Q4 2022.
  • 644 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.